
maverick therapeutics inc
Takeda Invests US$125 Million In Maverick’s T-Cell Platform
Maverick Therapeutics Inc. and Takeda will collaborate to develop a biologics platform for T-cell immunotherapy over the next five years.

Maverick Therapeutics Inc. and Takeda will collaborate to develop a biologics platform for T-cell immunotherapy over the next five years.